Sorrento Therapeutics Inc - Understand $srne stock

$SRNE Market Cap: $3.308 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$64.28M

TTM

Gross Margin

44.22%

TTM

Net Earnings

-$548.1M

TTM

Current Assets

$133.1M

Q2 2023

Current Liabilities

$264.9M

Q2 2023

Current Ratio

50.24%

Q2 2023

Total Assets

$456.7M

Q2 2023

Total Liabilities

$654.6M

Q2 2023

Book Value

-$198.0M

Q2 2023

Cash

$69.75M

Q2 2023

P/E

-0.006035

Sep 18, 2024 EST

Free Cash Flow

-$235.6M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$62.84M	$52.90M	$39.99M	$31.43M	$21.19M	$151.9M	$8.152M	$4.590M	$3.825M	$460.0K	$584.0K	$500.0K	$700.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	18.78%	32.31%	27.21%	48.31%	-86.04%	1762.81%	77.6%	20.0%	731.52%	-21.23%	16.8%	-28.57%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$62.84M	$52.90M	$39.99M	$31.43M	$21.19M	$151.9M	$8.152M	$4.590M	$3.825M	$460.0K	$584.0K	$500.0K	$700.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$33.50M	$13.03M	$9.900M	$12.20M	$7.060M	$3.945M	$811.0K	$1.950M	$2.043M	$4.000K	$0.00
Gross Profit	$29.40M	$39.87M	$30.00M	$19.20M	$14.13M	$147.9M	$7.341M	$2.640M	$1.782M	$456.0K	$584.0K
Gross Profit Margin	46.79%	75.37%	75.03%	61.08%	66.69%	97.4%	90.05%	57.52%	46.59%	99.13%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Selling, General & Admin	$182.3M	$196.9M	$116.2M	$103.6M	$63.60M	$38.30M	$24.20M	$20.10M	$10.00M	$6.300M	$1.600M	$1.200M	$1.100M	$500.0K	$0.00	$200.0K	$400.0K	$0.00
YoY Change	-7.39%	69.41%	12.16%	62.89%	66.06%	58.26%	20.4%	101.0%	58.73%	293.75%	33.33%	9.09%	120.0%		-100.0%	-50.0%
% of Gross Profit	620.07%	493.71%	387.33%	539.58%	450.01%	25.89%	329.66%	761.36%	561.17%	1381.58%	273.97%
Research & Development	$221.2M	$206.9M	$111.3M	$106.9M	$11.30M	$26.10M	$45.00M	$24.01M	$209.0K	$5.986M	$3.830M	$2.600M	$1.400M	$400.0K	$0.00		$0.00	$0.00
YoY Change	6.91%	85.85%	4.17%	845.5%	-56.69%	-42.0%	87.4%	11389.47%	-96.51%	56.28%	47.32%	85.71%	250.0%
% of Gross Profit	752.47%	518.95%	371.13%	556.66%	79.98%	17.65%	613.0%	909.58%	11.73%	1312.72%	655.89%
Depreciation & Amortization	$8.900M	$8.300M	$7.000M	$7.000M	$6.000M	$4.500M	$2.000M	$1.134M	$754.0K	$1.290M	$293.3K	$160.0K	$20.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	7.23%	18.57%	0.0%	16.67%	33.33%	125.0%	76.37%	50.4%	-41.57%	339.96%	83.31%	700.0%
% of Gross Profit	30.27%	20.82%	23.33%	36.46%	42.45%	3.04%	27.24%	42.95%	42.31%	282.98%	50.22%
Operating Expenses	$221.2M	$206.9M	$111.3M	$106.9M	$11.30M	$26.10M	$45.00M	$24.01M	$209.0K	$5.986M	$3.830M	$3.800M	$2.500M	$1.000M	$0.00	$200.0K	$400.0K	$0.00	$0.00	$0.00
YoY Change	6.91%	85.85%	4.17%	845.5%	-56.69%	-42.0%	87.4%	11389.47%	-96.51%	56.28%	0.8%	52.0%	150.0%		-100.0%	-50.0%
Operating Profit	-$504.3M	-$401.5M	-$244.5M	-$259.4M	-$150.4M	$25.34M	-$96.78M	-$74.01M	-$34.74M	-$21.67M	-$4.852M
YoY Change	25.62%	64.18%	-5.73%	72.44%	-693.74%	-126.18%	30.77%	113.01%	60.34%	346.58%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Interest Expense	$8.574M	$10.22M	$20.16M	$35.05M	$57.63M	$4.980M	$1.610M	$1.652M	$1.629M	$253.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-16.14%	-49.28%	-42.49%	-39.19%	1057.25%	209.32%	-2.54%	1.41%	543.87%
% of Operating Profit						19.66%
Other Income/Expense, Net	$0.00	-$28.00M		$0.00	$0.00	-$200.0K										$0.00	$0.00
YoY Change	-100.0%				-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Pretax Income	-$580.2M	-$462.7M	-$316.4M	-$363.5M	-$218.8M	-$24.93M	-$65.27M	-$9.719M	-$36.36M	-$21.91M	-$4.845M	-$3.200M	-$1.800M	-$900.0K	$0.00	-$300.0K	-$400.0K	$300.0K	$0.00	$0.00
YoY Change	25.4%	46.21%	-12.95%	66.13%	777.69%	-61.81%	571.55%	-73.27%	65.94%	352.24%	51.41%	77.78%	100.0%		-100.0%	-25.0%	-233.33%
Income Tax	-$2.416M	-$33.52M	-$2.014M	-$473.0K	-$6.274M	-$36.04M	-$896.0K	$36.31M	-$1.702M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income																		0.0%
Net Earnings	-$572.8M	-$428.3M	-$298.5M	-$292.1M	-$203.5M	$9.132M	-$60.92M	-$45.81M	-$34.66M	-$21.91M	-$4.845M	-$3.237M	-$1.808M	-$942.0K	-$26.00K	-$16.00K	-$400.0K	$300.0K	$0.00	$0.00
YoY Change	33.74%	43.51%	2.19%	43.49%	-2328.87%	-114.99%	32.99%	32.18%	58.17%	352.24%	49.68%	79.04%	91.93%	3523.08%	62.5%	-96.0%	-233.33%
Net Earnings / Revenue	-911.6%	-809.63%	-746.41%	-929.21%	-960.41%	6.01%	-747.34%	-998.06%	-906.07%	-4763.26%	-829.62%	-647.4%	-258.29%
Basic Earnings Per Share	-$1.37	-$1.45	-$1.30	-$2.20	-$1.92	$0.13	-$1.21	-$1.24
Diluted Earnings Per Share	-$1.37	-$1.45	-$1.30	-$2.35	-$1.92	$0.13	-$1.21	-$1.24	-$1.300M	-$1.460M	-$421.1K	-$323.2K	-$204.5K	-$147.5K	$0.00	-$1.000M	-$1.333M	$1.000M	$0.00	$0.00

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Cash & Short-Term Investments	$50.00M	$126.9M	$56.50M	$22.50M	$159.0M	$20.90M	$83.50M	$136.4M	$71.90M	$31.70M	$5.100M	$3.500M	$5.300M	$3.400M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-60.59%	124.57%	151.11%	-85.85%	660.77%	-74.97%	-38.78%	89.71%	126.81%	521.57%	45.71%	-33.96%	55.88%
Cash & Equivalents	$23.60M	$36.67M	$56.50M	$22.50M	$158.7M	$20.40M	$82.40M	$39.00M	$71.90M	$31.70M	$5.100M	$3.500M	$5.300M	$3.400M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Short-Term Investments	$26.30M	$90.22M			$300.0K	$400.0K	$1.100M	$97.40M
Other Short-Term Assets	$11.90M	$19.29M	$12.40M	$27.20M	$16.20M	$4.900M	$3.200M	$2.000M	$1.300M	$600.0K	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-38.3%	55.53%	-54.41%	67.9%	230.61%	53.13%	60.0%	53.85%	116.67%	500.0%
Inventory	$10.00M	$8.106M	$1.800M	$3.400M
Prepaid Expenses
Receivables	$24.50M	$18.72M	$15.50M	$14.50M	$3.800M	$2.200M	$1.700M	$900.0K	$700.0K	$400.0K	$100.0K	$100.0K	$200.0K	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$600.0K	$1.700M	$1.300M	$1.700M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$96.40M	$173.0M	$86.20M	$67.60M	$179.6M	$29.70M	$89.70M	$141.0M	$73.90M	$32.60M	$5.300M	$3.600M	$5.600M	$3.500M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-44.27%	100.68%	27.51%	-62.36%	504.71%	-66.89%	-36.38%	90.8%	126.69%	515.09%	47.22%	-35.71%	60.0%
Property, Plant & Equipment	$138.4M	$126.5M	$73.90M	$76.30M	$24.40M	$19.30M	$12.70M	$7.200M	$2.300M	$2.400M	$1.500M	$1.000M	$100.0K	$100.0K	$0.00
YoY Change	9.41%	71.17%	-3.15%	212.7%	26.42%	51.97%	76.39%	213.04%	-4.17%	60.0%	50.0%	900.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$17.20M	$51.27M	$256.4M	$262.2M	$265.0M	$270.0M	$189.0M	$170.1M	$10.00M	$0.00
YoY Change	-66.45%	-80.0%	-2.21%	-1.06%	-1.85%	42.86%	11.11%	1601.0%
Other Assets	$3.700M	$4.830M	$2.000M	$49.90M	$50.60M	$3.300M	$3.900M	$600.0K	$38.50M	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-23.4%	141.5%	-95.99%	-1.38%	1433.33%	-15.38%	550.0%	-98.44%	38400.0%
Total Long-Term Assets	$376.4M	$521.8M	$449.6M	$490.0M	$444.5M	$401.9M	$311.9M	$202.5M	$67.60M	$60.00M	$1.500M	$1.000M	$100.0K	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-27.87%	16.07%	-8.24%	10.24%	10.6%	28.86%	54.02%	199.56%	12.67%	3900.0%	50.0%	900.0%	0.0%
Total Assets	$472.8M	$694.8M	$535.8M	$557.6M	$624.1M	$431.6M	$401.6M	$343.5M	$141.5M	$92.60M	$6.800M	$4.600M	$5.700M	$3.600M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Accounts Payable	$47.50M	$27.41M	$24.70M	$27.60M	$13.80M	$9.900M	$8.300M	$1.300M	$1.700M	$2.200M	$400.0K	$200.0K	$200.0K	$300.0K	$100.0K	$0.00	$500.0K	$0.00	$100.0K	$100.0K
YoY Change	73.27%	10.99%	-10.51%	100.0%	39.39%	19.28%	538.46%	-23.53%	-22.73%	450.0%	100.0%	0.0%	-33.33%	200.0%		-100.0%		-100.0%	0.0%
Accrued Expenses	$255.3M	$71.02M	$43.70M	$38.00M	$23.60M	$11.80M	$8.300M	$6.300M	$2.700M	$2.000M	$100.0K	$100.0K	$200.0K	$0.00	$0.00			$0.00	$200.0K	$200.0K
YoY Change	259.49%	62.51%	15.0%	61.02%	100.0%	42.17%	31.75%	133.33%	35.0%	1900.0%	0.0%	-50.0%						-100.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.30M	$31.98M	$23.20M	$36.30M	$10.20M	$0.00	$200.0K	$4.800M	$3.300M	$400.0K	$0.00
YoY Change	-49.03%	37.84%	-36.09%	255.88%		-100.0%	-95.83%	45.45%	725.0%
Total Short-Term Liabilities	$327.9M	$139.5M	$96.50M	$115.2M	$61.60M	$79.00M	$76.10M	$30.90M	$9.600M	$5.500M	$600.0K	$400.0K	$600.0K	$400.0K	$100.0K	$0.00	$500.0K	$0.00	$300.0K	$300.0K
YoY Change	135.13%	44.51%	-16.23%	87.01%	-22.03%	3.81%	146.28%	221.88%	74.55%	816.67%	50.0%	-33.33%	50.0%	300.0%		-100.0%		-100.0%	0.0%
Long-Term Debt	$19.10M	$110.6M	$92.30M	$199.1M	$223.1M	$5.200M	$47.10M	$4.400M	$8.800M	$4.400M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-82.73%	19.86%	-53.64%	-10.76%	4190.38%	-88.96%	970.45%	-50.0%	100.0%
Other Long-Term Liabilities	$146.9M	$364.2M	$199.4M	$201.5M	$122.4M	$125.3M	$138.7M	$118.0M	$12.70M	$1.600M
YoY Change	-59.66%	82.64%	-1.04%	64.62%	-2.31%	-9.66%	17.54%	829.13%	693.75%
Total Long-Term Liabilities	$166.0M	$474.8M	$291.7M	$400.6M	$345.5M	$130.5M	$185.8M	$122.4M	$21.50M	$6.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-65.04%	62.77%	-27.18%	15.95%	164.75%	-29.76%	51.8%	469.3%	258.33%
Total Liabilities	$491.4M	$616.1M	$370.7M	$479.0M	$414.6M	$232.0M	$321.5M	$198.4M	$32.80M	$25.80M	$600.0K	$400.0K	$600.0K	$400.0K	$100.0K	$0.00	$500.0K	$0.00	$300.0K	$300.0K
YoY Change	-20.24%	66.19%	-22.61%	15.53%	78.71%	-27.84%	62.05%	504.88%	27.13%	4200.0%	50.0%	-33.33%	50.0%	300.0%		-100.0%		-100.0%	0.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2022	2021	2020	2019	2018	2017	2016	2015
Basic Shares Outstanding	419.3M	294.8M	229.8M	132.7M	106.2M	69.74M shares	50.36M shares	36.91M shares
Diluted Shares Outstanding	419.3M	294.8M	229.8M	140.5M	106.2M	70.38M shares	50.36M shares	36.91M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $3.3077 Million

About Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The firm is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Industry: Biological Products, (No Diagnostic Substances) Peers: Alector Inc Allovir Inc AnaptysBio Inc Anavex Life Sciences Corp CTI BIOPHARMA CORP Dyne Therapeutics Inc RAPT Therapeutics Inc INTERCEPT PHARMACEUTICALS, INC. Iteos Therapeutics Inc